INCY vs. TAK: Incyte vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Incyte (INCY) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while TAK is classified in Pharmaceuticals.

Incyte (INCY) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Incyte (INCY) has a non-negative beta of 0.78.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Incyte (INCY) at 7.84% sits in the top ROE quartile, while Takeda Pharmaceutical (TAK) at 0.56% is closer to the peer norm — stronger capital efficiency for INCY.

Incyte (INCY) at 6.71% retains a top-quartile share of revenue as profit, ahead of Takeda Pharmaceutical (TAK) at 0.87%, which keeps about the industry-typical share.

Both Incyte (INCY) at 33.72% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Incyte (INCY) at 21.22% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Both companies show strong earnings momentum, but Incyte (INCY) at 4,173.33% is the standout with EPS growth above its industry range; Takeda Pharmaceutical (TAK) at 77.96% also sits in the top quartile.

Growth Metrics

Financial Strength

Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Takeda Pharmaceutical (TAK) at 1.15 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TAK.

Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while Takeda Pharmaceutical (TAK) at 0.72 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Incyte (INCY) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both look expensive on trailing earnings: Incyte (INCY) at 61.05 sits in the richer P/E ratio quartile, and Takeda Pharmaceutical (TAK) at 300.29 is richer still, above its industry range.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Incyte (INCY) at 4.06 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile against book while Incyte (INCY) at 4.33 is valued near its industry’s middle — TAK is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics